Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCFA (US Health Care Financing Administration) lists products for special payments:

This article was originally published in Clinica

Executive Summary

The US Health Care Financing Administration (HCFA) has issued an expanded list of products that will be eligible for a special additional payment under Medicare's new outpatient prospective payment system due to go into effect on July 1. HCFA, which administers the Medicare health plan for the elderly and disabled, received 336 applications for more than 550 items and expects to make "pass-through" payments for 340 procedural codes encompassing 423 items. Those items that did not qualify for the two-to-three year pass-through payment will be automatically considered for placement in the new technology ambulatory classifications where they are likely to receive a comparatively high reimbursement, HCFA said. No further additions to the list can be made before the implementation date, HCFA said, but additional items will be reconsidered in October.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT076201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel